Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Other Accumulated Expenses (2017 - 2025)

Arcus Biosciences (RCUS) has 7 years of Other Accumulated Expenses data on record, last reported at $76.0 million in Q4 2023.

  • For Q4 2023, Other Accumulated Expenses changed 0.0% year-over-year to $76.0 million; the TTM value through Dec 2023 reached $76.0 million, changed 0.0%, while the annual FY2023 figure was $76.0 million, 0.0% changed from the prior year.
  • Other Accumulated Expenses reached $76.0 million in Q4 2023 per RCUS's latest filing, up from $37.0 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $76.0 million in Q4 2022 and bottomed at $121000.0 in Q3 2019.
  • Average Other Accumulated Expenses over 5 years is $24.5 million, with a median of $18.3 million recorded in 2020.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 92.37% in 2019, then skyrocketed 6459.16% in 2021.
  • A 5-year view of Other Accumulated Expenses shows it stood at $4.6 million in 2019, then skyrocketed by 300.42% to $18.3 million in 2020, then skyrocketed by 194.97% to $54.0 million in 2021, then surged by 40.74% to $76.0 million in 2022, then changed by 0.0% to $76.0 million in 2023.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $76.0 million in Q4 2023, $37.0 million in Q1 2023, and $76.0 million in Q4 2022.